TABLE 2.
Summary of adverse events due to any cause occurring in >1 subjecta
| Adverse event | No. of subjects with adverse event in treatment group |
||||
|---|---|---|---|---|---|
| TQ + DHA-PQP (n = 24) | TQ + AL (n = 24) | DHA-PQP (n = 24) | AL (n = 24) | TQ (n = 24) | |
| Fatigue | 1 | 1 | 0 | 1 | 0 |
| Influenza-like illness | 1 | 1 | 1 | 0 | 0 |
| Medical device site reaction | 1 | 0 | 2 | 0 | 0 |
| Asthenia | 0 | 1 | 1 | 0 | 0 |
| Feeling hot | 1 | 0 | 1 | 0 | 0 |
| Pyrexia | 1 | 1 | 0 | 0 | 0 |
| Headache | 3 | 4 | 3 | 1 | 1 |
| Dizziness | 0 | 2 | 1 | 0 | 0 |
| Nausea | 2 | 1 | 2 | 0 | 0 |
| Diarrhea | 1 | 1 | 2 | 0 | 0 |
| Abdominal pain | 1 | 1 | 0 | 0 | 0 |
| Contact dermatitis | 2 | 0 | 1 | 1 | 0 |
| Ventricular tachycardia | 0 | 0 | 1 | 1 | 0 |
| Upper RTI | 0 | 0 | 0 | 1 | 1 |
| Throat irritation | 0 | 0 | 1 | 1 | 0 |
| Decreased appetite | 0 | 1 | 1 | 1 | 0 |
a
TQ, tafenoquine; DHA-PQP, dihydroartemisinin-piperaquine; AL, artemether-lumefantrine; RTI, respiratory tract infection.